Drugs / OZUREPRUBART
last change Jul 2026 re-read 2 minutes ago

OZUREPRUBART

also known as JYB1904 · RPT904

Monoclonal antibody

Developed for
chronic idiopathic urticaria · allergic asthma · allergic disease · food allergy · perennial allergic rhinitis
Investigated by
Jemincare

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT07513857 May 2026 → Jul 2027 expected allergic disease Jemincare Not yet recruiting No outcome recorded
Phase 1 NCT05449535 May 2022 → Jan 2023 Jemincare Completed No outcome recorded
Phase 22 trials
Phase 2 NCT06509334 Aug 2024 → Jul 2026 overdue chronic idiopathic urticaria Jemincare Recruiting No outcome recorded
Phase 2 NCT06438757 Jun 2024 → Nov 2025 allergic asthma Jemincare Completed No outcome recorded
Phase 31 trial
Phase 3 NCT07402213 Mar 2026 → Jun 2027 expected chronic idiopathic urticaria Jemincare Not yet recruiting No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07459452 Comparator Apr 2026 → Oct 2027 expected perennial allergic rhinitis Jemincare Not yet recruiting No outcome recorded
Phase 2 NCT07220811 Comparator Oct 2025 → Apr 2027 expected food allergy RAPT Therapeutics, Inc. Recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as OZUREPRUBART ChEMBL registry synonym — accepted as the source's own label CHEMBL6068159
Known as JYB1904 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07513857
5

NCT07402213

NCT05449535

NCT06438757

NCT07459452

NCT06509334

Known as RPT904 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07220811
Action Inhibit “anti-IgE” NCT07220811
Modality Monoclonal antibody “RPT904, a next-generation anti-IgE monoclonal antibodyNCT07220811
1

CHEMBL6068159

Route Subcutaneous subcutaneous injection in the deltoid region of the upper arm.” NCT05449535